Examkin

Question

Difficulty: MediumClinical Preventive Services and Screening

A 2-month-old girl is brought to the clinic for a routine well-child evaluation. She was born at 39 weeks gestation via an uncomplicated vaginal delivery. Her mother has severe Crohn disease and was maintained on infliximab therapy throughout her pregnancy, including the third trimester. The infant is exclusively breastfed, feeding well, and gaining weight appropriately. Both parents are non-smokers, and the family history is otherwise unremarkable. Vital signs show a temperature of 37.1°C (98.8°F), heart rate of 128/min, and respiratory rate of 28/min. Physical examination reveals a well-appearing, alert infant with normal growth parameters and a normal abdominal examination. According to the standard immunization schedule, the infant is due for several immunizations today. Which of the following is the most appropriate immunization strategy for this patient?

  1. Administer routine inactivated vaccines and defer the live-attenuated rotavirus vaccineAnswer
  2. B
    Administer all age-appropriate routine vaccines, including the live-attenuated rotavirus vaccine
  3. C
    Defer all immunizations until the infant is at least 6 months of age to allow clearance of maternal antibodies
  4. D
    Administer routine inactivated vaccines but substitute the oral poliovirus vaccine for the inactivated poliovirus vaccine
  5. E
    Administer the live-attenuated rotavirus vaccine and defer the diphtheria-tetanus-acellular pertussis vaccine

Answer

The most appropriate strategy is to administer routine inactivated vaccines (DTaP, IPV, Hib, PCV, HepB) while deferring the live-attenuated rotavirus vaccine due to the infant's exposure to a biologic immunosuppressant in utero.
The correct approach is to administer all scheduled inactivated vaccines (such as DTaP, IPV, Hib, and PCV) but withhold the live-attenuated rotavirus vaccine. Infliximab is a monoclonal IgG1 antibody directed against tumor necrosis factor-alpha (TNF-alpha). When given to a pregnant woman during the second and third trimesters, it actively crosses the placenta, leading to detectable and often therapeutic serum drug levels in the newborn. Because infliximab is an immunosuppressive agent, exposed infants are considered functionally immunocompromised. The CDC and American Academy of Pediatrics recommend that live-attenuated vaccines (e.g., rotavirus) be deferred for at least 6 months after birth in these infants to prevent severe, potentially fatal vaccine-strain infections. Inactivated vaccines are safe and should be administered according to the normal schedule.

Step-by-Step Solution

1
Evaluate the mother's medication history during pregnancy.
The mother received infliximab (a monoclonal TNF-alpha inhibitor) during the third trimester.
IgG monoclonal antibodies actively cross the placenta in the third trimester, exposing the fetus to systemic levels of the drug.
2
Determine the infant's immune status based on maternal exposure.
The infant is considered functionally immunocompromised for up to 6 months of age.
Biologic agents can persist in the infant's circulation for months after birth, impairing their cell-mediated immunity.
3
Apply the CDC immunization guidelines for immunocompromised infants.
Live-attenuated vaccines (like rotavirus) are strictly contraindicated, while inactivated vaccines should be given on schedule.
Live vaccines can cause uninhibited, severe systemic infections in immunocompromised hosts, whereas inactivated vaccines are safe.

Key Concept

Infants born to mothers treated with biologic immunosuppressants (e.g., infliximab) in the third trimester should not receive live-attenuated vaccines for the first 6 months of life.
Estimated Time:1m 0s
Rate this question

Topics

Clinical Preventive Services and Screening

More questions from this topic